Antihyperlipidemic Drugs
Classification, Pharmacokinetics, Mechanism of Action, Indications, Adverse Effects, Contraindications, and Drug Interactions
Introduction to Antihyperlipidemic Drugs
- Used to
lower lipid levels in the blood
- Aim to
prevent cardiovascular diseases
- Act on different pathways involved in lipid metabolism
- Statins (HMG-CoA reductase inhibitors)
Eg. Simvastatin, Atorvastatin - Fibrates (PPAR-α activators)
Clofibrate, Gemfibrozil - Bile Acid Sequestrants (Resins)
Colestipol - Inhibitor of Triglyceride Synthesis
Nicotinic Acid (Niacin) - Other Agents
Omega Fatty Acids
Inhibit HMG-CoA reductase enzyme
- Reduce
cholesterol synthesis in the liver
- Increase
LDL receptor expression → enhanced LDL clearance
- Decrease
plasma LDL and total cholesterol levels
- Hypercholesterolemia
- Prevention
of cardiovascular diseases
- Post-myocardial
infarction patients
- Muscle
pain (myopathy, rhabdomyolysis in severe cases)
- Hepatotoxicity
(monitor liver enzymes)
- Gastrointestinal
disturbances
- Pregnancy
and lactation
- Active
liver disease
- Drug interactions (e.g., CYP3A4 inhibitors increase statin levels)
- Activate
PPAR-α receptors
- Increase
lipoprotein lipase activity → enhances triglyceride breakdown
- Decrease VLDL and increase HDL levels
- Hypertriglyceridemia
- Type III hyperlipoproteinemia
- Gallstone
formation
- Myopathy
(increased risk when combined with statins)
- Gastrointestinal
disturbances
- Severe
hepatic or renal dysfunction
- Gallbladder
disease
- Drug interactions (increased risk of myopathy with statins)
- Bind
bile acids in the intestine → prevent reabsorption
- Increase conversion of cholesterol to bile acids → lowers LDL levels
- Hypercholesterolemia
(adjunct therapy)
- Used in patients who cannot tolerate statins
- Constipation
and bloating
- Interference with fat-soluble vitamin absorption (A, D, E, K)
- Bowel
obstruction
- Severe hypertriglyceridemia
- Inhibits
triglyceride synthesis in the liver
- Reduces
VLDL and LDL levels
- Increases HDL levels
- Hypertriglyceridemia
- Combined hyperlipidemia
- Flushing
and itching (prostaglandin-mediated, reduced by aspirin)
- Hepatotoxicity
- Hyperuricemia (may exacerbate gout)
- Peptic
ulcer disease
- Severe
liver disease
- Gout
- Reduce
triglyceride levels
- Anti-inflammatory
properties
- Cardioprotective
effects
Presentation for Antihyperlipidemic Drugs
END OF THE CHAPTER
You may also like read more:
0 comments:
Post a Comment